Loading...
XSTO
BOUL
Market cap34mUSD
Jun 11, Last price  
8.40SEK
1D
-2.33%
1Q
-6.87%
Jan 2017
-88.00%
IPO
-27.27%
Name

Boule Diagnostics AB

Chart & Performance

D1W1MN
XSTO:BOUL chart
No data to show
P/E
—
P/S
0.58
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.21%
Rev. gr., 5y
2.29%
Revenues
559m
-2.23%
168,693,500175,391,166229,421,000246,155,000275,301,000276,804,000306,687,000331,407,000400,735,000427,793,000424,400,000498,916,000400,458,000463,344,000548,088,000571,329,000558,600,000
Net income
-223m
L
-5,549,061-10,548,23318,891,00011,711,00010,959,000-70,125,00030,265,00015,352,00036,033,00037,239,00041,031,00037,548,000-47,965,00023,272,00012,728,00024,977,000-223,300,000
CFO
47m
-9.30%
4,310,8948,203,59716,159,0005,444,00010,948,00015,675,00030,985,00022,324,00019,875,00057,715,00022,663,00053,976,00075,239,00043,284,000-11,353,00051,377,00046,600,000
Dividend
May 06, 20220.38946 SEK/sh
Earnings
Jul 21, 2025

Profile

Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. The company provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning products under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer and diagnostics systems under the Exigo brand. It sells its products directly in Sweden and the United States, as well as through distributors internationally. The company serves hospitals, clinics, laboratories, healthcare centers and veterinary clinics, and other diagnostics companies. It has operations in Sweden, the United States, Mexico, and Russia. The company was founded in 1956 and is headquartered in Spånga, Sweden.
URL
https://www.boule.com/
IPO date
Jun 23, 2011
Employees
200
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
558,600
-2.23%
571,329
4.24%
548,088
18.29%
Cost of revenue
775,800
528,059
515,346
Unusual Expense (Income)
NOPBT
(217,200)
43,270
32,742
NOPBT Margin
7.57%
5.97%
Operating Taxes
(45,200)
5,123
8,121
Tax Rate
11.84%
24.80%
NOPAT
(172,000)
38,147
24,621
Net income
(223,300)
-994.02%
24,977
96.24%
12,728
-45.31%
Dividends
(10,679)
Dividend yield
2.48%
Proceeds from repurchase of equity
(560)
123,799
BB yield
0.13%
-28.79%
Debt
Debt current
142,500
97,480
105,069
Long-term debt
66,800
92,600
121,102
Deferred revenue
Other long-term liabilities
3,400
8,317
3,133
Net debt
186,600
152,799
79,649
Cash flow
Cash from operating activities
46,600
51,377
(11,353)
CAPEX
(8,900)
(82,700)
(74,961)
Cash from investing activities
(85,900)
(82,714)
(74,961)
Cash from financing activities
24,400
(25,506)
140,550
FCF
(147,685)
56,896
(33,776)
Balance
Cash
22,700
37,281
96,904
Long term investments
49,618
Excess cash
8,715
119,118
Stockholders' equity
(115,100)
138,893
125,741
Invested Capital
583,100
640,871
524,508
ROIC
6.55%
5.39%
ROCE
6.66%
5.02%
EV
Common stock shares outstanding
38,835
38,833
28,477
Price
8.98
-19.96%
11.22
-25.70%
15.10
-69.06%
Market cap
348,736
-19.96%
435,706
1.33%
430,003
-68.72%
EV
535,336
588,505
509,652
EBITDA
(217,200)
67,885
59,917
EV/EBITDA
8.67
8.51
Interest
12,600
11,264
9,821
Interest/NOPBT
26.03%
30.00%